结核病增强疫苗
Boosting vaccine for tuberculosis.
作者信息
Brooks J V, Frank A A, Keen M A, Bellisle J T, Orme I M
机构信息
Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado 80523, USA.
出版信息
Infect Immun. 2001 Apr;69(4):2714-7. doi: 10.1128/IAI.69.4.2714-2717.2001.
Abstract
An effective new vaccine for the control of tuberculosis is badly needed. While current research attempts to improve vaccination are concentrating on new prophylactic or immunotherapeutic vaccines, virtually no emphasis has been placed on boosting individuals already inoculated with Mycobacterium bovis BCG. It is shown here that mice vaccinated with BCG gradually lose their capacity to resist an aerosol challenge infection as they age. However, if these mice are inoculated with the 30-kDa mycolyl transferase A protein in midlife, after challenge when aged they express levels of protection in the lungs comparable to those of young mice, associated with minimal pathological damage.
摘要
迫切需要一种有效的新型结核病控制疫苗。虽然目前旨在改进疫苗接种的研究主要集中在新型预防性或免疫治疗性疫苗上，但几乎没有强调增强已经接种卡介苗的个体的免疫力。本文表明，接种卡介苗的小鼠随着年龄增长逐渐失去抵抗气溶胶攻击感染的能力。然而，如果这些小鼠在中年时接种30 kDa分枝杆菌酸转移酶A蛋白，在老年时受到攻击后，它们肺部的保护水平与年轻小鼠相当，且病理损伤最小。
相似文献
1
Boosting vaccine for tuberculosis.
Infect Immun. 2001 Apr;69(4):2714-7. doi: 10.1128/IAI.69.4.2714-2717.2001.
2
Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Vaccine. 2006 Apr 12;24(16):3353-64. doi: 10.1016/j.vaccine.2005.12.066. Epub 2006 Feb 6.
3
Subunit vaccine candidate AMM down-regulated the regulatory T cells and enhanced the protective immunity of BCG on a suitable schedule.
Scand J Immunol. 2012 Mar;75(3):293-300. doi: 10.1111/j.1365-3083.2011.02666.x.
4
Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting.
Int J Immunogenet. 2012 Apr;39(2):183-90. doi: 10.1111/j.1744-313X.2011.01066.x. Epub 2011 Dec 8.
5
Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
Vaccine. 2009 Jan 1;27(1):28-37. doi: 10.1016/j.vaccine.2008.10.034. Epub 2008 Oct 31.
6
Mucosal prime-boost vaccination for tuberculosis based on TLR triggering OprI lipoprotein from Pseudomonas aeruginosa fused to mycolyl-transferase Ag85A.
Immunol Lett. 2007 Jul 31;111(1):26-35. doi: 10.1016/j.imlet.2007.04.010. Epub 2007 May 22.
7
A live attenuated BCG vaccine overexpressing multistage antigens Ag85B and HspX provides superior protection against Mycobacterium tuberculosis infection.
Appl Microbiol Biotechnol. 2015 Dec;99(24):10587-95. doi: 10.1007/s00253-015-6962-x. Epub 2015 Sep 12.
8
Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.
Infect Immun. 2006 Aug;74(8):4634-43. doi: 10.1128/IAI.00517-06.
9
The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs.
Infect Immun. 2004 Nov;72(11):6622-32. doi: 10.1128/IAI.72.11.6622-6632.2004.
10
Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
Vaccine. 2009 Oct 19;27(44):6179-85. doi: 10.1016/j.vaccine.2009.08.018. Epub 2009 Aug 25.
引用本文的文献
1
A Review of COVID-19 Modelling Strategies in Three Countries to Develop a Research Framework for Regional Areas.
Viruses. 2021 Oct 29;13(11):2185. doi: 10.3390/v13112185.
2
A 2-Dose AERAS-402 Regimen Boosts CD8 Polyfunctionality in HIV-Negative, BCG-Vaccinated Recipients.
Front Immunol. 2021 Jun 11;12:673532. doi: 10.3389/fimmu.2021.673532. eCollection 2021.
3
NOD2/RIG-I Activating Adjuvant Enhances the Efficacy of BCG Vaccine Against Tuberculosis in Mice.
Front Immunol. 2020 Dec 7;11:592333. doi: 10.3389/fimmu.2020.592333. eCollection 2020.
4
Adenovirus-prime and baculovirus-boost heterologous immunization achieves sterile protection against malaria sporozoite challenge in a murine model.
Sci Rep. 2018 Mar 1;8(1):3896. doi: 10.1038/s41598-018-21369-y.
5
Boosting BCG-primed responses with a subunit Apa vaccine during the waning phase improves immunity and imparts protection against Mycobacterium tuberculosis.
Sci Rep. 2016 May 13;6:25837. doi: 10.1038/srep25837.
6
The Mycobacterium bovis BCG prime-Rv0577 DNA boost vaccination induces a durable Th1 immune response in mice.
Acta Biochim Biophys Sin (Shanghai). 2016 Apr;48(4):385-90. doi: 10.1093/abbs/gmw010. Epub 2016 Feb 27.
7
Cloning of the Recombinant Cytochrome P450 Cyp141 Protein of Mycobacterium tuberculosis as a Diagnostic Target and Vaccine Candidate.
Iran Red Crescent Med J. 2014 Nov 5;16(11):e18001. doi: 10.5812/ircmj.18001. eCollection 2014 Nov.
8
Tuberculosis vaccine types and timings.
Clin Vaccine Immunol. 2015 Mar;22(3):249-57. doi: 10.1128/CVI.00718-14. Epub 2014 Dec 24.
9
Attrition of T-cell functions and simultaneous upregulation of inhibitory markers correspond with the waning of BCG-induced protection against tuberculosis in mice.
PLoS One. 2014 Nov 24;9(11):e113951. doi: 10.1371/journal.pone.0113951. eCollection 2014.
10
Production and Purification of Mycolyl Transferase B of Mycobacterium tuberculosis.
Tanaffos. 2011;10(4):23-30.
本文引用的文献
1
Therapy of tuberculosis in mice by DNA vaccination.
Nature. 1999 Jul 15;400(6741):269-71. doi: 10.1038/22326.
2
New vaccines against tuberculosis. The status of current research.
Infect Dis Clin North Am. 1999 Mar;13(1):169-85, vii-viii. doi: 10.1016/s0891-5520(05)70049-0.
3
Vaccination against tuberculosis: recent progress.
Adv Vet Med. 1999;41:135-43. doi: 10.1016/s0065-3519(99)80013-5.
4
Tuberculosis among elderly persons, as observed among nursing home residents.
Int J Tuberc Lung Dis. 1998 Sep;2(9 Suppl 1):S64-70.
5
Expression of memory immunity in the lung following re-exposure to Mycobacterium tuberculosis.
Tuber Lung Dis. 1997;78(1):67-73. doi: 10.1016/s0962-8479(97)90017-4.
6
The global threat of drug-resistant tuberculosis.
N Engl J Med. 1998 Jun 4;338(23):1689-90. doi: 10.1056/NEJM199806043382309.
7
Evaluation of new vaccines in the mouse and guinea pig model of tuberculosis.
Infect Immun. 1998 Jun;66(6):2951-9. doi: 10.1128/IAI.66.6.2951-2959.1998.
8
Does the efficacy of BCG decline with time since vaccination?
Int J Tuberc Lung Dis. 1998 Mar;2(3):200-7.
9
Immunity to mycobacteria with emphasis on tuberculosis: implications for rational design of an effective tuberculosis vaccine.
Chem Immunol. 1998;70:21-59. doi: 10.1159/000058699.
10
Assessment of worldwide tuberculosis control. WHO Global Surveillance and Monitoring Project.
Lancet. 1997 Aug 30;350(9078):624-9. doi: 10.1016/s0140-6736(97)04146-9.
Zotero 插件